INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
13 nov. 2024 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Nov. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that...
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
31 oct. 2024 16h05 HE
|
INmune Bio, Inc.
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness...
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
28 oct. 2024 08h00 HE
|
INmune Bio, Inc.
“Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials” Webinar to be Held on November 7, 2024, at 1 PM ET. Poster on EMACC Sensitivity and Performance in...
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
24 oct. 2024 15h03 HE
|
INmune Bio, Inc.
Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell Multi-year study published has implications for many CNS diseases including...
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
24 oct. 2024 09h30 HE
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a...
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
11 oct. 2024 08h30 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and...
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
30 sept. 2024 08h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Sept. 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and...
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
26 sept. 2024 08h00 HE
|
INmune Bio, Inc.
BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer...
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
17 sept. 2024 08h30 HE
|
INmune Bio, Inc.
BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of...
INmune Bio Announces $13.0 Million Registered Direct Offering
13 sept. 2024 08h30 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developing...